동구바이오제약

006620KOSDAQ의약품 제조업

64.0 / 100

Reference Date: 2026-04-13

Financial Score25.0 / 40

News Sentiment20.0 / 25

Momentum7.0 / 20

Disclosure12.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 6.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

DonggubioPharm operates diversified businesses including pharmaceutical manufacturing, new technology investments, marketing services, healthcare services, and pharmaceutical wholesale and consulting. In Q4 2024, its pharmaceutical segment achieved sales of 2,475 billion won, a 15.2% increase compared to the previous year. The company is expanding into new sectors such as biotech investments and medical tourism to enhance growth potential.

Number of Employees

440people

Average Salary

56.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

2.75Industry Average 14.808.0Point

Half of industry avg (excellent)

PBR

0.96Industry Average 1.044.0Point

In line with industry avg

ROE

38.95Industry Average 4.427.0Point

8.8x industry avg (excellent)

Debt Ratio

30.70Industry Average 11.980.0Point

2.6x industry avg (risky)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼20.1% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 17.3% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Positive
[바이오스냅] 조아제약, 고함량 NMN을 함유 '텔로X2 NMN' 출시
동구바이오제약이 에이치투메디와 차세대 필링 솔루션 '라라닥터' 유통 계약을 체결하며 메디컬 에스테틱 시장 진출을 알렸습니다.
Positive
동구바이오제약, 에이치투메디와 '라라닥터' 국내 독점 유통 계약
동구바이오제약은 에이치투메디와 '라라닥터' 국내 독점 유통 계약을 체결하여 피부과 처방 1위 인프라를 활용한 메디컬 에스테틱 시장 진입을 본격화하고 있습니다.

Detailed Momentum

52-week position3.0Point

52w lower range (26%)

Current 5,110Won52-week high 6,09052-week low 4,765

1-month return2.0Point

1m -6.58% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

10 totalPositive 1Neutral 9Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-02
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-01
Neutral주식매수선택권부여에관한신고2026-04-01
Neutral사업보고서 (2025.12)2026-03-23
Neutral감사보고서제출2026-03-23